» Articles » PMID: 36073854

Alzheimer's Drug PBT2 Interacts with the Amyloid β 1-42 Peptide Differently Than Other 8-Hydroxyquinoline Chelating Drugs

Overview
Journal Inorg Chem
Specialty Chemistry
Date 2022 Sep 8
PMID 36073854
Authors
Affiliations
Soon will be listed here.
Abstract

Although Alzheimer's disease (AD) was first described over a century ago, it remains the leading cause of age-related dementia. Innumerable changes have been linked to the pathology of AD; however, there remains much discord regarding which might be the initial cause of the disease. The "amyloid cascade hypothesis" proposes that the amyloid β (Aβ) peptide is central to disease pathology, which is supported by elevated Aβ levels in the brain before the development of symptoms and correlations of amyloid burden with cognitive impairment. The "metals hypothesis" proposes a role for metal ions such as iron, copper, and zinc in the pathology of AD, which is supported by the accumulation of these metals within amyloid plaques in the brain. Metals have been shown to induce aggregation of Aβ, and metal ion chelators have been shown to reverse this reaction . 8-Hydroxyquinoline-based chelators showed early promise as anti-Alzheimer's drugs. Both 5-chloro-7-iodo-8-hydroxyquinoline (CQ) and 5,7-dichloro-2-[(dimethylamino)methyl]-8-hydroxyquinoline (PBT2) underwent unsuccessful clinical trials for the treatment of AD. To gain insight into the mechanism of action of 8HQs, we have investigated the potential interaction of CQ, PBT2, and 5,7-dibromo-8-hydroxyquinoline (B2Q) with Cu(II)-bound Aβ(1-42) using X-ray absorption spectroscopy (XAS), high energy resolution fluorescence detected (HERFD) XAS, and electron paramagnetic resonance (EPR). By XAS, we found CQ and B2Q sequestered ∼83% of the Cu(II) from Aβ(1-42), whereas PBT2 sequestered only ∼59% of the Cu(II) from Aβ(1-42), suggesting that CQ and B2Q have a higher relative Cu(II) affinity than PBT2. From our EPR, it became clear that PBT2 sequestered Cu(II) from a heterogeneous mixture of Cu(II)Aβ(1-42) species in solution, leaving a single Cu(II)Aβ(1-42) species. It follows that the Cu(II) site in this Cu(II)Aβ(1-42) species is inaccessible to PBT2 and may be less solvent-exposed than in other Cu(II)Aβ(1-42) species. We found no evidence to suggest that these 8HQs form ternary complexes with Cu(II)Aβ(1-42).

Citing Articles

Newer Therapeutic Approaches in Treating Alzheimer's Disease: A Comprehensive Review.

Reddi Sree R, Kalyan M, Anand N, Mani S, Gorantla V, Sakharkar M ACS Omega. 2025; 10(6):5148-5171.

PMID: 39989768 PMC: 11840625. DOI: 10.1021/acsomega.4c05527.


Multi-target-directed therapeutic strategies for Alzheimer's disease: controlling amyloid-β aggregation, metal ion homeostasis, and enzyme inhibition.

Yoo J, Lee J, Ahn B, Han J, Lim M Chem Sci. 2025; 16(5):2105-2135.

PMID: 39810997 PMC: 11726323. DOI: 10.1039/d4sc06762b.


Metal Ion Signaling in Biomedicine.

Rodriguez R, Muller S, Colombeau L, Solier S, Sindikubwabo F, Caneque T Chem Rev. 2025; 125(2):660-744.

PMID: 39746035 PMC: 11758815. DOI: 10.1021/acs.chemrev.4c00577.


Copper homeostasis and neurodegenerative diseases.

Wang Y, Li D, Xu K, Wang G, Zhang F Neural Regen Res. 2024; 20(11):3124-3143.

PMID: 39589160 PMC: 11881714. DOI: 10.4103/NRR.NRR-D-24-00642.


MAD-microbial (origin of) Alzheimer's disease hypothesis: from infection and the antimicrobial response to disruption of key copper-based systems.

Min J, Sarlus H, Harris R Front Neurosci. 2024; 18:1467333.

PMID: 39416952 PMC: 11480022. DOI: 10.3389/fnins.2024.1467333.


References
1.
Hussain I, Powell D, Howlett D, Tew D, Meek T, Chapman C . Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci. 1999; 14(6):419-27. DOI: 10.1006/mcne.1999.0811. View

2.
Bush A . The metal theory of Alzheimer's disease. J Alzheimers Dis. 2012; 33 Suppl 1:S277-81. DOI: 10.3233/JAD-2012-129011. View

3.
Sahoo B, Cox S, Ramamoorthy A . High-resolution probing of early events in amyloid-β aggregation related to Alzheimer's disease. Chem Commun (Camb). 2020; 56(34):4627-4639. PMC: 7254607. DOI: 10.1039/d0cc01551b. View

4.
Squitti R, Ghidoni R, Simonelli I, Ivanova I, Colabufo N, Zuin M . Copper dyshomeostasis in Wilson disease and Alzheimer's disease as shown by serum and urine copper indicators. J Trace Elem Med Biol. 2017; 45:181-188. DOI: 10.1016/j.jtemb.2017.11.005. View

5.
Adlard P, Bush A . Metals and Alzheimer's disease. J Alzheimers Dis. 2006; 10(2-3):145-63. DOI: 10.3233/jad-2006-102-303. View